Article

Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.

Center for the Study of Human Cognition, Department of Psychology, University of Oslo, Oslo, Norway.
Cerebral Cortex (Impact Factor: 8.31). 09/2010; 20(9):2069-79. DOI: 10.1093/cercor/bhp279
Source: PubMed

ABSTRACT Reduced levels of beta-amyloid(1-42) (Abeta1-42) and increased levels of tau proteins in the cerebrospinal fluid (CSF) are found in Alzheimer's disease (AD), likely reflecting Abeta deposition in plaques and neuronal and axonal damage. It is not known whether these biomarkers are associated with brain atrophy also in healthy aging. We tested the relationship between CSF levels of Abeta1-42 and tau (total tau and tau phosphorylated at threonine 181) proteins and 1-year brain atrophy in 71 cognitively normal elderly individuals. Results showed that under a certain threshold value, levels of Abeta1-42 correlated highly with 1-year change in a wide range of brain areas. The strongest relationships were not found in the regions most vulnerable early in AD. Above the threshold level, Abeta1-42 was not related to brain changes, but significant volume reductions as well as ventricular expansion were still seen. It is concluded that Abeta1-42 correlates with brain atrophy and ventricular expansion in a subgroup of cognitively normal elderly individuals but that reductions independent of CSF levels of Abeta1-42 is common. Further research and follow-up examinations over several years are needed to test whether degenerative pathology will eventually develop in the group of cognitively normal elderly individuals with low levels of Abeta1-42.

Download full-text

Full-text

Available from: Christine Fennema-Notestine, Jul 06, 2015
1 Follower
 · 
156 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atrophic changes in early Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) have been proposed as biomarkers for detection and monitoring. We analyzed magnetic resonance imaging (MRI) atrophy rate from baseline to 1 year in 4 groups of participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI): AD (n = 152), converters from MCI to probable AD (MCI-C, n = 60), stable MCI (MCI-S, n = 261), and healthy controls (HC, n = 200). Scans were analyzed using multiple methods, including voxel-based morphometry (VBM), regions of interest (ROIs), and automated parcellation, permitting comparison of annual percent change (APC) in neurodegeneration markers. Effect sizes and the sample required to detect 25% reduction in atrophy rates were calculated. The influence of APOE genotype on APC was also evaluated. AD patients and converters from MCI to probable AD demonstrated high atrophy APCs across regions compared with minimal change in healthy controls. Stable MCI subjects showed intermediate atrophy rates. APOE genotype was associated with APC in key regions. In sum, APC rates are influenced by APOE genotype, imminent MCI to AD conversion, and AD-related neurodegeneration.
    Neurobiology of aging 08/2010; 31(8):1401-18. DOI:10.1016/j.neurobiolaging.2010.04.029 · 4.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A complex interaction between genetic and environmental risk factors has often been a suspected trigger for the development of neurodegenerative disease. Yet of all the possible environmental risk factors, trauma to the central nervous system is one of the most consistent candidates for initiating the molecular cascades that result in several neurodegenerative diseases including Alzheimer's disease (AD). In almost all of the studies investigating traumatic brain injury and AD risk, AD was diagnosed based on clinical criteria for probable or possible AD, without neuropathological verification. Recent evidence also suggests that mild traumatic brain injury, including repetitive concussions and subconcussive trauma, can provoke another distinctive neurodegeneration termed chronic traumatic encephalopathy. Because most reports were based on clinical diagnostic criteria that may lack the specificity to rule out other causes of dementia, it is possible that the increased incidence of dementia following head injuries is due to CTE, alone or in conjunction with other neurodegenerative conditions such as AD. The search for, and validation of, biomarkers for specific neurodegenerative diseases provide disease diagnosis and indicators of risk and disease progression, and offer a means to monitor therapeutic efficacy.
    09/2012; 1(3). DOI:10.1007/s13670-012-0020-7